Supplemental material
Open access
2,812
Views
1
CrossRef citations to date
0
Altmetric
Oncology
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L
Karen L. Reckampa Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9213-0325
, https://orcid.org/0000-0002-9213-0325
Huamao M. Linb Global Evidence and Outcome, Takeda Development Center Americas Inc., Lexington, MA, USAhttps://orcid.org/0000-0002-8399-8966
, Holly Cranmerc Global Market Access, Takeda Pharmaceuticals International Co., London, UKhttps://orcid.org/0000-0002-9067-3422
, Yanyu Wub Global Evidence and Outcome, Takeda Development Center Americas Inc., Lexington, MA, USA
, Pingkuan Zhangd Clinical Science; Takeda Development Center Americas Inc., Lexington, MA, USA
, Stephen Kaye Department of Statistics, Model Outcomes Ltd., Cheshire, UKhttps://orcid.org/0000-0002-2104-7460
, Laura J. Waltonf Global Value and Access, Takeda Pharmaceuticals International AG, Zurich, Switzerland
, Junwu Sheng Statistics, Takeda Development Center Americas Inc., Lexington, MA, USA
, Sanjay Popath Lung Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, UKhttps://orcid.org/0000-0003-2087-4963
& D. Ross Camidgei Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA
show all
Pages 1587-1593
|
Received 28 Mar 2022, Accepted 08 Jul 2022, Published online: 29 Jul 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.